Previous Close | 272.20 |
Open | 270.08 |
Bid | 271.50 x 0 |
Ask | 271.66 x 0 |
Day's Range | 268.50 - 274.80 |
52 Week Range | 253.48 - 325.00 |
Volume | |
Avg. Volume | 3,812,976 |
Market Cap | 329.044B |
Beta (5Y Monthly) | 0.08 |
PE Ratio (TTM) | 28.99 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 8.80 (3.24%) |
Ex-Dividend Date | Nov 22, 2023 |
1y Target Est | N/A |
Mindray (SZSE: 300760), a global leader in medical devices and solutions, introduces high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.
Mindray (SZSE: 300760), a global leader in providing advanced medical device solutions, has unveiled upgrades to its A7 and A5 anaesthesia systems under the A Series Anaesthesia. These enhancements incorporate innovative technologies that empower anaesthesiologists to deliver precise anaesthesia, leading to greater patient safety and efficiency throughout the perioperative period.
Mindray, a leading global provider of medical devices and solutions and Operation Smile, a global nonprofit dedicated to transforming the lives of patients and their communities by increasing access to safe surgery and providing high-quality cleft surgery and comprehensive care, today announced a new 10-year partnership. This solidifies a strategic partnership between the two organizations to collaborate on improving the quality of health care and providing life-changing medical interventions to